Insmed Inc (INSM) Company Profile & Statistics

Insmed Inc
INSM
(Nasdaq - US)
Closed
73.88
+1.21 (+1.67%)
in:usd•As of: Nov 21, 2024 15:59 UTC -5
Open
73.06
High
74.06
Low
71.01

About Insmed Inc

CEO

William H. Lewis

Headquarters

700 us highway 202/206

bridgewater, nj 08807, united states

Auditor

Ernst & Young LLP

Employees

912

Share Holders

176

Website

www.insmed.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.

Insmed Inc Statistics

Valuation Measures

Market Capitalization ²	13.22B
Enterprise Value	13.74B
Enterprise Value/EBITDA (ttm)	-17.06
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	27.28
Price to Sales (ttm)	38.46
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	77.24%
Operating Margin (ttm)	-252.01%
Profit Margin (ttm)	-249.79%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-98.06%
Return on Assets (ttm)	-54.43%

Income Statement

Revenue (ttm)	342.96M
Revenue Per Share (ttm)	1.92
Gross Profit (ttm)	264.92M
EBITDA (ttm)³	-805.50M
Net Income Avi to Common (ttm)	-864.29M
Diluted EPS (ttm)	-5.55

Share Statistics

Beta (5Y Monthly)	1.12
52-Week Change	200.08%
S&P500 52-Week Change	30.55%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	178.90M
Dividend Yield	0.00%
Float ⁴	170.67M
% Held by Insiders	4.60%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	1.47B
Total Cash Per Share (mrq)	8.21
Total Debt (mrq)	982.54M
Total Debt/Equity (mrq)	203.25%
Current Ratio (mrq)	6.37%
Quick Ratio (mrq)	5.99%
Book Value Per Share (mrq)	2.70

Cash Flow

Operating Cash Flow Per Share (ytd)	-2.81
Free Cash Flow (ytd)	-503.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Insmed Inc

Trade With A Regulated Broker